Summit stock rises as non-opioid painkillers show positive results in pilot studies


Daniele Grizelj

Vertex Pharmaceuticals (NASDAQ:VRTX) is trading around +6.5% on Tuesday, after reporting positive results from a Phase 3 program evaluating VX-548, its non-opioid drug candidate for moderate to severe acute pain.

VX-548 was found to significantly improve pain compared to placebo

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *